Abstract: PX-478 (S-2-amino-3-[4′-N,N,-bis(chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride) is a potent, orally available small-molecule inhibitor of hypoxia-inducible factor-1α (HIF-1α). It is the first HIF-1α inhibitor to enter Phase I clinical trials. While initially recognized for its antitumor properties, recent research has extensively explored its pharmacological activity in metabolic diseases and ischemic conditions. PX-478 exerts its effects by suppressing the transcription and translation of HIF-1α, as well as inhibiting its deubiquitination. In the context of metabolic diseases and ischemia, PX-478 demonstrates highly context-dependent effects. In conditions driven by pathological HIF-1α overactivation—such as atherosclerosis, portal hypertensive gastropathy, and hepatic fibrosis—PX-478 provides therapeutic benefits by reducing glycolysis, oxidative stress, and inflammation. Conversely, in acute ischemic events like ischemic stroke and diabetic renal ischemia-reperfusion injury, HIF-1α plays a crucial protective role; thus, its inhibition by PX-478 exacerbates tissue damage, increases blood-brain barrier permeability, and blocks protective mitophagy. This review synthesizes current literature on PX-478, detailing its pharmacological activity, molecular mechanisms, structural insights, limitations, and future therapeutic perspectives.
1. Introduction
Hypoxia-inducible factor-1α (HIF-1α) is a master transcriptional regulator of the cellular response to hypoxia, playing a critical role in maintaining oxygen homeostasis, regulating energy metabolism, and modulating cell survival [1][7]. PX-478, chemically known as S-2-amino-3-[4′-N,N,-bis(chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride, is a highly selective small-molecule inhibitor of HIF-1α [3][5][9]. It holds the distinction of being the first HIF-1α inhibitor to enter Phase I clinical trials [5].
While PX-478 has demonstrated significant efficacy in suppressing tumor growth and angiogenesis across various cancers (including oral squamous cell carcinoma, cervical cancer, and lung cancer) [2][5][11], emerging research has pivoted toward its role in metabolic diseases and ischemia. Because HIF-1α is deeply intertwined with metabolic reprogramming (such as glycolysis) and cellular responses to ischemic injury, PX-478 serves as a vital pharmacological tool. It has been utilized to dissect the dual nature of HIF-1α signaling, revealing that while HIF-1α inhibition can prevent pathological vascular remodeling and inflammation in some metabolic disorders, it can also abolish critical adaptive and protective mechanisms during acute ischemic events [1][3][10].
2. Pharmacological Activity
Ischemia and Reperfusion Injury: The role of PX-478 in ischemia is complex, as HIF-1α often acts as a protective factor during acute hypoxic stress. In diabetic mice subjected to transient middle cerebral artery occlusion (tMCAO), treatment with endothelial progenitor cells (EPCs) normally protects blood-brain barrier (BBB) integrity and reduces infarct volume via HIF-1α upregulation. Administration of PX-478 completely blocked these beneficial effects, leading to increased brain infarct volume, exacerbated neurological deficits, and enlarged gap formations in brain microvascular endothelial cells [1]. Similarly, in diabetic renal ischemia-reperfusion injury (I/RI), the circadian gene BMAL1 protects renal cells by promoting mitophagy. PX-478 treatment attenuated this protective effect, resulting in reduced cell viability, decreased ATP content, compromised mitochondrial membrane potential (MMP), and exacerbated apoptosis [3].
Metabolic Diseases and Complications: In diabetic retinopathy (DR), the Heyingwuzi formulation (HYWZF) protects human retinal capillary endothelial cells (HRCECs) from high glucose-induced damage by promoting HIF-1α-mediated mitophagy. The introduction of PX-478 reversed these protective effects, confirming that HIF-1α is essential for cellular survival under diabetic hyperglycemic conditions [6]. However, in atherosclerosis—a disease exacerbated by metabolic dysfunction and low wall shear stress (WSS)—PX-478 demonstrated therapeutic potential. In Apoe-/- mice with endothelial cell-specific knockout of IRP2, low WSS induced abnormal iron accumulation and HIF expression. Treatment with PX-478 successfully suppressed the exacerbation of atherosclerosis [10].
Gastric Mucosal Lesions and Fibrosis: In portal hypertensive gastropathy (PHG) and gastric cancer models, hypoxia induces mitochondrial dysfunction and excessive glycolysis. PX-478 treatment alleviated these lesions by reducing lactic acid production, repressing Drp1-mediated mitochondrial fission, and decreasing reactive oxygen species (ROS) [7]. Furthermore, in hepatic fibrosis models, PX-478 repressed the pericyte functions of hepatic stellate cells (HSCs), including angiogenic cytokine production, migration, adhesion, and contraction [12].
Autoimmune and Inflammatory Modulation: In peripheral blood immune cells from patients with myasthenia gravis, PX-478 significantly decreased glycolysis levels and downregulated the expression of activation markers (CD80 and CD86) in B cells, highlighting its ability to modulate immune cell metabolism [13].
3. Molecular Mechanism of Action
Inhibition of HIF-1α Expression and Stability: PX-478 suppresses HIF-1α at multiple levels. It decreases HIF-1α mRNA levels, inhibits its translation, and prevents its deubiquitination, which leads to an accumulation of polyubiquitinated HIF-1α that is subsequently degraded [2][3][9]. By inhibiting HIF-1α, PX-478 downregulates downstream target genes, including vascular endothelial growth factor (VEGF) and various glycolytic enzymes [4][5].
Modulation of Mitophagy and Apoptosis: HIF-1α regulates mitochondrial autophagy (mitophagy) via the BNIP3/NIX pathway. PX-478 treatment reduces BNIP3 expression, thereby inhibiting mitophagy. In ischemic models, this leads to a decrease in the LC3B II/I ratio and an accumulation of damaged mitochondria (evidenced by increased p62, TOMM20, and COX IV), which ultimately triggers apoptosis and cell death [3][6]. Conversely, in cancer cells, PX-478 induces apoptosis and cell cycle arrest, often acting synergistically with ROS inducers [2].
Repression of Glycolysis and Energy Metabolism: PX-478 directly impacts cellular energy metabolism by downregulating key glycolytic enzymes that are normally transactivated by HIF-1α. Treatment with PX-478 significantly reduces the expression of lactate dehydrogenase A (LDHA), hexokinase-2 (HK2), pyruvate kinase M2 (PKM2), and glucose transporter 1 (GLUT1), thereby decreasing lactic acid concentrations and altering the metabolic profile of cells [7][13].
Regulation of Mitochondrial Dynamics and Inflammasomes: In hypoxic gastric mucosal lesions, PX-478 blocks Drp1-dependent mitochondrial fission and prevents the interaction between Drp1 and Fis1. This action mitigates mitochondrial oxidative stress and subsequently represses the activation of the NLRP3 inflammasome, thereby preventing pyroptosis (evidenced by reduced cleaved caspase-1 and IL-1β secretion) [7].
Signaling Pathway Intersections: PX-478 influences several kinase pathways. In osteoarthritic osteoblasts, while PX-478 does not inhibit total AKT protein, it significantly decreases the levels of phosphorylated AKT (p-AKT), linking HIF-1α inhibition to the PI3K/AKT signaling axis [4]. It also downregulates the EMT pathway protein TWIST, contributing to its anti-migratory and anti-invasive effects [8].
4. Structure-Activity Relationship (SAR)
PX-478 is formulated as S-2-amino-3-[4′-N,N,-bis(chloroethyl)amino]phenyl propionic acid N-oxide dihydrochloride [5][9]. While detailed structural modifications and their corresponding activity shifts are not exhaustively detailed in the provided literature, the compound's specific N-oxide dihydrochloride salt form and bis(chloroethyl)amino moiety are integral to its oral bioavailability and its unique capacity to selectively interfere with both the transcription and translation of HIF-1α, as well as its deubiquitination process [2][3]. This multi-tiered interference makes it a highly potent suppressor of HIF-1α compared to agents that only target a single regulatory step.
5. Current Limitations
The primary limitation of PX-478 lies in the context-dependent nature of HIF-1α signaling. While inhibiting HIF-1α is highly beneficial in halting tumor progression, angiogenesis, and atherosclerosis [5][10], it can be severely detrimental in acute ischemic conditions. In ischemic stroke and diabetic renal ischemia-reperfusion injury, HIF-1α acts as a critical survival factor that maintains blood-brain barrier integrity and clears damaged mitochondria via mitophagy. Administering PX-478 in these contexts exacerbates tissue damage, increases vascular permeability, and promotes apoptosis [1][3].
Furthermore, PX-478 has been shown to possess immunosuppressive side effects in the tumor microenvironment. It dose-dependently impairs the proliferation and cytotoxic function of engineered immune cells, such as mesoCAR T cells, which rely on HIF-1α-driven glycolysis for their effector functions [11]. Finally, studies note the necessity for alternative pharmacological inhibitors or genetic knockdown models to definitively rule out potential off-target effects of PX-478 [11].
6. Future Perspectives
Future therapeutic applications of PX-478 will require precise, context-specific administration. In oncology, there is strong potential for combination therapies; for instance, PX-478 exhibits potent synergistic effects when combined with metabolic modulators like dichloroacetate (DCA) or ROS inducers like arsenic trioxide (ATO), enhancing apoptosis in various cancer cell lines [2].
In the realm of metabolic diseases, PX-478 holds promise for treating conditions driven by chronic, pathological HIF-1α activation, such as atherosclerosis, portal hypertensive gastropathy, and hepatic fibrosis [7][10][12]. Additionally, its ability to modulate immune cell metabolism—such as downregulating B cell activation in myasthenia gravis—opens new avenues for repurposing PX-478 in autoimmune diseases [13]. However, strict clinical guidelines must be established to avoid the use of HIF-1α inhibitors in patients at risk for acute ischemic events (e.g., stroke or acute kidney injury), where HIF-1α-mediated mitophagy and vascular protection are indispensable [1][3].
